587 related articles for article (PubMed ID: 26974250)
21. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.
Basu P; Malvi SG; Joshi S; Bhatla N; Muwonge R; Lucas E; Verma Y; Esmy PO; Poli URR; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Prabhu PR; Kannan TPRA; Varghese R; Shastri SS; Anantharaman D; Gheit T; Tommasino M; Sauvaget C; Pillai MR; Sankaranarayanan R
Lancet Oncol; 2021 Nov; 22(11):1518-1529. PubMed ID: 34634254
[TBL] [Abstract][Full Text] [Related]
22. Impact of HPV vaccination with Gardasil® in Switzerland.
Jacot-Guillarmod M; Pasquier J; Greub G; Bongiovanni M; Achtari C; Sahli R
BMC Infect Dis; 2017 Dec; 17(1):790. PubMed ID: 29273004
[TBL] [Abstract][Full Text] [Related]
23. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women.
Tanaka H; Shirasawa H; Shimizu D; Sato N; Ooyama N; Takahashi O; Terada Y
J Obstet Gynaecol Res; 2017 Oct; 43(10):1597-1601. PubMed ID: 28707725
[TBL] [Abstract][Full Text] [Related]
24. Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and Young Women Immunized With the Human Papillomavirus Vaccine.
Schlecht NF; Diaz A; Nucci-Sack A; Shyhalla K; Shankar V; Guillot M; Hollman D; Strickler HD; Burk RD
JAMA Netw Open; 2021 Aug; 4(8):e2121893. PubMed ID: 34424304
[TBL] [Abstract][Full Text] [Related]
25. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
26. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus-vaccinated and unvaccinated women: a population-based cohort study.
Krog L; Lycke KD; Kahlert J; Randrup TH; Jensen PT; Rositch AF; Hammer A
Am J Obstet Gynecol; 2024 Apr; 230(4):430.e1-430.e11. PubMed ID: 38569830
[TBL] [Abstract][Full Text] [Related]
27. Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands.
Schurink-van 't Klooster TM; Siebers AG; Hoes J; van Kemenade FJ; Berkhof J; Bogaards JA; de Melker HE
Cancer Med; 2023 May; 12(10):11786-11794. PubMed ID: 36965085
[TBL] [Abstract][Full Text] [Related]
28. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
[TBL] [Abstract][Full Text] [Related]
29. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
30. Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario.
Lee GY; Inthasorn P; Laowahutanont P; Lawpoolsri S; Kamolratanakul S; Lungchukiet P; Oh J; Termrungruanglert W; Taechakraichana N; Pitisuttithum P
Vaccine; 2022 Mar; 40(13):1968-1976. PubMed ID: 35190207
[TBL] [Abstract][Full Text] [Related]
31. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
Joura EA; Garland SM; Paavonen J; Ferris DG; Perez G; Ault KA; Huh WK; Sings HL; James MK; Haupt RM;
BMJ; 2012 Mar; 344():e1401. PubMed ID: 22454089
[TBL] [Abstract][Full Text] [Related]
32. Status of HPV vaccination among HPV-infected women aged 20-60 years with abnormal cervical cytology in South Korea: a multicenter, retrospective study.
Seong J; Ryou S; Yoo M; Lee J; Kim K; Jee Y; Cho CH; Kim SM; Hong SR; Jeong DH; Lee WC; Park JS; Kim TJ; Kee MK
J Gynecol Oncol; 2020 Jan; 31(1):e4. PubMed ID: 31788994
[TBL] [Abstract][Full Text] [Related]
33. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
34. A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada.
Steben M; Tan Thompson M; Rodier C; Mallette N; Racovitan V; DeAngelis F; Stutz M; Rampakakis E
J Obstet Gynaecol Can; 2018 Dec; 40(12):1635-1645. PubMed ID: 30341021
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs.
Markowitz LE; Drolet M; Perez N; Jit M; Brisson M
Vaccine; 2018 Aug; 36(32 Pt A):4806-4815. PubMed ID: 29802000
[TBL] [Abstract][Full Text] [Related]
37. Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus-Vaccinated Women-Results From a Tertiary Referral Center.
Domröse CM; Wieland U; Pilch H; Einzmann T; Schömig-Markiefka B; Mallmann P; Silling S; Mallmann MR
J Low Genit Tract Dis; 2022 Apr; 26(2):122-126. PubMed ID: 35019900
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of HPV vaccination in Belize.
Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
[TBL] [Abstract][Full Text] [Related]
39. High-risk human papillomavirus cervical infections among healthy women in Guadeloupe.
Cordel N; Ragin C; Trival M; Tressières B; Janky E
Int J Infect Dis; 2015 Dec; 41():13-6. PubMed ID: 26597118
[TBL] [Abstract][Full Text] [Related]
40. Primary care providers human papillomavirus vaccine recommendations for the medically underserved: a pilot study in U.S. Federally Qualified Health Centers.
Roland KB; Benard VB; Greek A; Hawkins NA; Saraiya M
Vaccine; 2014 Sep; 32(42):5432-5. PubMed ID: 25131744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]